We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




黑色素瘤生物标志物预测检查点阻断剂的响应

By LabMedica International staff writers
Posted on 27 Aug 2018
Print article
图片:巴氏染色的细胞样本中恶性黑色素瘤被染色后的显微图像(图片蒙Nephron惠赐)。
图片:巴氏染色的细胞样本中恶性黑色素瘤被染色后的显微图像(图片蒙Nephron惠赐)。

免疫检查点抑制剂类药物能调动免疫系统攻击癌症,近年来,这类药物的使用极大改善了晚期黑色素瘤患者的预后。这些药物阻断遏制免疫系统的检查点分子,并释放T细胞这样的免疫防护因子,以识别和攻击癌症。

 

联用抗细胞毒性T淋巴细胞抗原4 (CTLA-4)与抗程序性细胞死亡蛋白1 (PD-1)疗法提升了抗肿瘤免疫力,对晚期黑色素瘤患者的好处远胜单用其中任何一种疗法。目前没有办法预测对抗CTLA-4癌症免疫疗法的反应。

 

美国马萨诸塞州波士顿市Dana-Farber癌症研究所(www.dana-farber.org)的科学家及其同行检查了以前未治黑色素瘤患者肿瘤细胞的主要组织相容性复合体(MHC) I类与II类蛋白质表达,并建立结果与转录分析和基因组分析之间的关联以及与抗CTLA-4、抗PD-1或组合疗法的临床效果之间的关联。

 

181例病例中的78(43%)观察到黑色素瘤MHC I类膜表达大部(>50%的细胞)或全部损失,科研小组发现,这种现象与HLA-AHLA-BHLA-CB2M的转录抑制相关,并能预测对抗CTLA-4疗法的原发耐受性,但是预测不了对抗PD-1疗法的耐受。 181例病例中的55(30%)观察到大于1%的细胞有黑色素瘤MHC II类膜表达,与γ干扰素(IFN-γ)IFN-γ介导的基因特征有关,且能预测对PD-1疗法的反应,但是预测不了对抗CTLA-4疗法的反应。

 

该研究的论文发表于2018718日的《科学》杂志《转化医学》分册。第一作者、病理医师Scott Rodig博士说:我们通过观察黑色素瘤如何逃过免疫系统的检测,或许能发现一种药剂就能产生良好效果的患者,不损失药效,且病人的忍受力更好。

 

作者总结说,抗CTLA-4疗法要起效需要有稳定的黑色素瘤MHC I类表达。相反,当MHC I类表达不足时,抗PD-1疗法的主要效果与已有的IFN-γ介导的免疫活化有关,它包括肿瘤特有的MHC II类表达以及先天免疫的成分。

Related Links:

Dana-Farber癌症研究所>>> www.dana-farber.org


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.